Dasatinib Combined with Interferon-alfa Induces a Complete Cytogenetic Response and Major Molecular Response in a Patient with Chronic Myelogenous Leukemia Harboring the T315I BCR-ABL1 Mutation

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian et al. · New England Journal of Medicine · 2006 · 1.8K citations · Full text

Medicine, Hematology, Pharmacology +15

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Ellen Weisberg, Paul W. Manley, Werner Breitenstein et al. · Cancer Cell · 2005 · 1.5K citations · Full text

Pharmacy, Medicinal Chemistry, Molecular Biology +6

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia

Alejandro Gutiérrez, Takaomi Sanda, Ruta Grebliunaite et al. · Blood · 2009 · 438 citations · Full text

Medicine, Molecular Biology, Oncology +14

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

Elias Jabbour, Hagop M. Kantarjian, Dan Jones et al. · Leukemia · 2006 · 387 citations

Medicine, Hematology, Oncology +11

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

Claude Preudhomme, Joëlle Guilhot, Franck E. Nicolini et al. · New England Journal of Medicine · 2010 · 386 citations

Pharmacy, Hematology, Pharmacotherapy +6